Diclofenac
- PDF / 169,604 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 32 Downloads / 198 Views
1 S
Hypersensitivity: case report A 44-year-old woman developed hypersensitivity manifesting as face swelling and general skin rash during treatment with diclofenac for headache. On 28 January 2020, the woman presented to the out-patient clinic of a hospital in Taiwan due to one day history of fever and headache. She was a non smoker and had no history of foreign travel in past 3 months; however, her husband had recently returned from Wuhan, China. Under suspicion of COVID-19 infection from her husband, she was admitted to the airborne isolation unit. Later, COVID-19 infection was confirmed (her husband also tested positive for COVID-19 infection later and was hospitalised). During hospitalisation, she was prescribed diclofenac [route and dosage not stated] for headache; however, she developed hypersensitivity manifesting as face swelling and general skin rash [duration of treatment to reaction onset not stated]. Hypersensitivity to diclofenac therpay was considered. Therefore, the woman’s diclofenac therapy was discontinued, along with all other ongoing unspecified prescription medications. Additionally, she received three dosses of dexamethasone as treatment. Subsequently, the rash and face swelling subsided. On day-5 of hospitalisation, her fever and headache improved. On day 17, tests showed negative result for COVID-19 infection. Liao C-H, et al. How do we decide to de-isolate COVID-19 patients?. Journal of Microbiology, Immunology and Infection 53: 386-388, No. 3, Jun 2020. Available from: 803498180 URL: http://doi.org/10.1016/j.jmii.2020.03.025
0114-9954/20/1819-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 29 Aug 2020 No. 1819
Data Loading...
